B12 Treatment Options
Effective treatment combines the likely cause, symptom severity, and ongoing response. The goal is stable recovery, not waiting for symptoms to return.
Treat the person, not one number
Symptoms, risk factors, and response to treatment should guide decisions alongside blood results.
Identify the underlying cause
Dietary deficiency, malabsorption, and pernicious anaemia may need different long-term pathways.
Monitor and adjust early
If symptoms return before the next dose, review dosing interval and cofactors instead of waiting.
Treatment Pathways
No Neurological Symptoms
Often 6 x 1000 mcg hydroxocobalamin IM over 2 weeks, then maintenance every 8-12 weeks.
- Used across pernicious anaemia, malabsorption, and many non-dietary causes.
- For dietary deficiency, oral maintenance may be considered with close review.
- If symptoms recur early, bring doses closer together and reassess cofactors.
With Neurological Symptoms
Often 1000 mcg hydroxocobalamin IM on alternate days until improvement plateaus, then taper to a stable schedule.
- Early intensive treatment aims to reduce risk of persistent neurological harm.
- Maintenance should prevent relapse between injections, not follow a rigid interval if symptoms return.
- Escalate quickly if worsening neurological signs appear.
Cofactors That Commonly Need Review
Recovery can stall when cofactors are not optimised. Targets and dosing should always be interpreted with local laboratory ranges and your clinician's advice.
Folate (B9)
Target: Aim for upper third of local reference range
Why it matters: B12 therapy increases demand on folate pathways and can expose low stores.
Typical support: 5 mg folic acid or methylfolate if clinically advised.
Ferritin (Iron Stores)
Target: Common functional target around 80-100 ug/L (interpret locally)
Why it matters: Improved red cell production during B12 treatment requires adequate iron availability.
Typical support: Iron supplementation only when deficiency is confirmed.
Vitamin B6
Target: Stay comfortably in normal range
Why it matters: Supports methylation pathways and homocysteine handling.
Typical support: Low-dose B-complex is commonly used if advised by clinician.
Follow-Up Plan
- 1Track symptom trend, function, and relapse timing between doses.
- 2Review cofactors and safety markers if recovery stalls.
- 3Document clear escalation triggers for urgent neurological changes.
- 4Re-check cause pathway if response is weaker than expected.
Useful Next Steps
Safety Note
This page is educational and is not a substitute for clinical advice. Always discuss diagnosis, dosing, and changes to treatment with your GP or specialist clinician.
Source: British National Formulary (BNF).